Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Spyre drug for inflammatory bowel disease shows promise in early study

 April 13, 2026

BioPharma Dive

The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.

Clinical DataImmunology & InflammationRead full story

Post navigation

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma →
← Alamar, Hemab, Kailera, and Seaport advance IPOs

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com